To systematically evaluate the efficacy of Chinese patent medicines for regulating qi and activating blood circulation in the treatment of angina pectoris.Methods:China National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD)，PubMed and Cochrane Library were all retrieved from the establishment of the database until July 2020.Randomized controlled trials of Chinese patent medicines for regulating qi and activating blood for the treatment of coronary heart disease and angina pectoris were selected.The quality of the literature was evaluated according to the Jadad scale，and statistical analysis was performed using Stata 16 and R3.5.1 software.Results:A total of 58 studies were included，with a total sample size of 7,467 cases.The measures included 8 Chinese medicines，covering Danshen Tablet(DST)，Danshen Dropping Pills(DSDP)，Suxiaojiuxin Pills(SXJXP)，Liqi Huoxue Pills(LQHXP)，Guanxin Danshen Dropping Pills(GXDSP)，Xinkeshu Tablets(XKST)，Xuefu Zhuyu Capsules(XFZYC)and Yindan Xinnaotong Capsule(YDXNTC).The results showed that in terms of the efficacy of angina pectoris，the cumulative probability ranking was:SXJXP(0.815)>DSDP(0.804)>YDXNTC(0.801)>GXDSP(0.447)>XKST(0.444)>XFZYC(0.378)>LQHXP(0.247)>DST(0.063).In terms of the effective rate of electrocardiogram，the rank of cumulative probability was:SXJXP(0.790)>GXDSP(0.784)>XFZYC(0.734)>LQHXP(0.569)>XKST(0.519)>YDXNTC(0.362)>DSDP(0.242)>DST(0.000).Taking the 2 outcomes into consideration，the effects of SXJXP，GXDSP and XFZYC were better.Conclusion:For patients with angina pectoris caused by qi stagnation and blood stasis，SXJXP can be given preference in clinical.However，in consideration of limited quality of included studies，this conclusion still needs to be further verified by high-quality studies.In addition，we should select Chinese patent medicine in combination with individual situations.